DK2582683T3 - Behandling af gigt og hyperurikæmi - Google Patents
Behandling af gigt og hyperurikæmi Download PDFInfo
- Publication number
- DK2582683T3 DK2582683T3 DK11796324.9T DK11796324T DK2582683T3 DK 2582683 T3 DK2582683 T3 DK 2582683T3 DK 11796324 T DK11796324 T DK 11796324T DK 2582683 T3 DK2582683 T3 DK 2582683T3
- Authority
- DK
- Denmark
- Prior art keywords
- gout
- less
- allopurinol
- compound
- instances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse i profylakse eller behandling af allopurinol-refraktær gigt.
2. Lesinurad-natrium og allopurinol til anvendelse ifølge krav 1.
3. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge krav 1, hvor gigten er kendetegnet ved tilstedeværelse af store akkumulerede aflejringer af urinsyre eller tophi.
4. Lesinurad eller et farmaceutisk acceptabelt salt og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor administration af lesinurad eller det farmaceutisk acceptable salt deraf til patienten er oral administration.
5. Lesinurad eller et farmaceutisk acceptabelt salt og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor administrationen af lesinurad eller det farmaceutisk acceptable salt deraf sker om morgenen.
6. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor den daglige dosis af lesinurad eller det farmaceutisk acceptable salt deraf er 200 mg.
7. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor den daglige dosis af lesinurad eller det farmaceutisk acceptable salt deraf er 400 mg.
8. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor dosen af allopurinol er 100 mg til 300 mg.
9. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge et hvilket som helst af kravene 2 til 7 til administration sammen med fødevare.
10. Allopurinol og farmaceutisk sammensætning, der omfatter lesinurad eller et farmaceutisk acceptabelt salt deraf, til anvendelse ifølge et hvilket som helst af kravene 1 til 9.
11. Allopurinol og farmaceutisk sammensætning, der omfatter lesinurad eller et farmaceutisk acceptabelt salt deraf, til anvendelse ifølge et hvilket som helst af kravene som 1 til 10, hvor dosen af allopurinol er 100 mg til 300 mg.
12. Lesinurad-natrium og allopurinol til anvendelse ifølge et hvilket som helst af kravene 2 til 8, hvor lesinuradnatriummet er amorft.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35500410P | 2010-06-15 | 2010-06-15 | |
US41144910P | 2010-11-08 | 2010-11-08 | |
US201161430522P | 2011-01-06 | 2011-01-06 | |
US201161489420P | 2011-05-24 | 2011-05-24 | |
PCT/US2011/040398 WO2011159732A1 (en) | 2010-06-15 | 2011-06-14 | Treatment of gout and hyperuricemia |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2582683T3 true DK2582683T3 (da) | 2018-06-06 |
Family
ID=45348529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11796324.9T DK2582683T3 (da) | 2010-06-15 | 2011-06-14 | Behandling af gigt og hyperurikæmi |
Country Status (18)
Country | Link |
---|---|
US (3) | US9216179B2 (da) |
EP (1) | EP2582683B1 (da) |
JP (1) | JP5964821B2 (da) |
CA (1) | CA2802407C (da) |
CY (1) | CY1120473T1 (da) |
DK (1) | DK2582683T3 (da) |
ES (1) | ES2670700T3 (da) |
HR (1) | HRP20180780T1 (da) |
HU (1) | HUE038265T2 (da) |
LT (1) | LT2582683T (da) |
NO (1) | NO2019008I1 (da) |
PL (1) | PL2582683T3 (da) |
PT (1) | PT2582683T (da) |
RS (1) | RS57275B1 (da) |
SI (1) | SI2582683T1 (da) |
TR (1) | TR201806828T4 (da) |
WO (1) | WO2011159732A1 (da) |
ZA (1) | ZA201300055B (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3659601A1 (en) | 2010-03-30 | 2020-06-03 | Ardea Biosciences, Inc. | Treatment of gout |
SI2582683T1 (en) * | 2010-06-15 | 2018-07-31 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricaemia |
EA026101B1 (ru) * | 2011-11-03 | 2017-03-31 | Ардеа Биосайнсиз, Инк. | Применение 3,4-дизамещенного пиридинового соединения для снижения уровня мочевой кислоты в сыворотке крови |
AR091651A1 (es) | 2012-07-03 | 2015-02-18 | Ardea Biosciences Inc | Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico |
US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
CN103613552A (zh) * | 2013-12-02 | 2014-03-05 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法 |
CN103755651A (zh) * | 2013-12-23 | 2014-04-30 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法 |
WO2015095703A1 (en) | 2013-12-20 | 2015-06-25 | Crystal Pharmatech, Inc. | Novel salts and co-crystals of lesinurad |
JP2015160847A (ja) * | 2014-02-28 | 2015-09-07 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 小分子のキサンチンオキシダーゼ阻害剤および使用方法 |
CN105622531A (zh) | 2015-04-03 | 2016-06-01 | 南京明德新药研发股份有限公司 | 轴手性异构体及其制备方法和制药用途 |
WO2016203436A1 (en) * | 2015-06-19 | 2016-12-22 | Dr. Reddy's Laboratories Limited | Amorphous and amorphous solid dispersion of lesinurad and their preparation |
EP3112334A1 (en) | 2015-06-29 | 2017-01-04 | DPx Fine Chemicals Austria GmbH & CoKG | Process for manufacturing 1-cyclopropyl-naphthalenes |
JP6976946B2 (ja) * | 2015-12-08 | 2021-12-08 | アーディア・バイオサイエンシーズ・インコーポレイテッドArdea Biosciences, Inc. | 生理活性の強い、urat1のインヒビターを含む医薬組成物 |
CA3060185A1 (en) | 2018-10-26 | 2020-04-26 | The Procter & Gamble Company | Sanitary tissue product rolls |
CA3060193C (en) | 2018-10-26 | 2023-05-09 | The Procter & Gamble Company | Paper towel rolls |
CA3060180A1 (en) | 2018-10-26 | 2020-04-26 | The Procter & Gamble Company | Sanitary tissue product rolls |
US20220288038A1 (en) * | 2019-08-21 | 2022-09-15 | The University Of Tokyo | Abcc11 inhibitor |
CN110824067A (zh) * | 2019-12-11 | 2020-02-21 | 天津药物研究院有限公司 | 一种非布司他中基因毒性杂质的检测方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063788A1 (ja) | 2003-12-26 | 2005-07-14 | Kissei Pharmaceutical Co., Ltd. | ベンズイミダゾール誘導体及びその医薬用途 |
US20060189811A1 (en) | 2004-07-23 | 2006-08-24 | Fujiyakuhin Co., Ltd. | Process for producing 1,2,4-triazole compound and intermediate therefor |
DK2135608T3 (da) | 2004-08-25 | 2012-01-23 | Ardea Biosciences Inc | S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase |
WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
BRPI0806608A2 (pt) | 2007-01-19 | 2011-09-06 | Takeda Pharmaceuticals North America Inc | métodos para prevenir ou reduzir o número de surtos agudos de gota utilizando inibidores xantina oxidoredutase e agentes anti-inflamatórios |
NZ595035A (en) | 2007-11-27 | 2012-11-30 | Ardea Biosciences Inc | Substituted diazole and triazole compounds and compositions and methods of use |
US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
US8242154B2 (en) * | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
CA2735828C (en) | 2008-09-04 | 2013-07-23 | Esmir Gunic | Substituted-(naphthalen-1-yl)-1h-imidazoles and their use for modulating uric acid levels |
US20100160351A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
WO2010135530A2 (en) * | 2009-05-20 | 2010-11-25 | Ardea Biosciences, Inc. | Compounds, compositions and methods for modulating uric acid levels |
EP2266966A1 (en) | 2009-06-11 | 2010-12-29 | Chemo Ibérica, S.A. | A process for the preparation of febuxostat |
MY161482A (en) | 2010-01-08 | 2017-04-14 | Ardea Biosciences Inc | Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof |
EP3659601A1 (en) | 2010-03-30 | 2020-06-03 | Ardea Biosciences, Inc. | Treatment of gout |
SI2582683T1 (en) * | 2010-06-15 | 2018-07-31 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricaemia |
ES2706066T3 (es) * | 2010-07-02 | 2019-03-27 | Univ Health Network | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas |
CA2813555C (en) * | 2010-10-15 | 2014-11-25 | Ardea Biosciences, Inc. | Methods for treating hyperuricemia and related diseases |
EA022301B1 (ru) * | 2010-12-30 | 2015-12-30 | Ардеа Биосайнсиз, Инк. | Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение |
EA201370247A1 (ru) | 2011-05-24 | 2014-07-30 | Ардеа Биосайнсиз, Инк. | Гипертония и гиперурикемия |
-
2011
- 2011-06-14 SI SI201131474T patent/SI2582683T1/en unknown
- 2011-06-14 LT LTEP11796324.9T patent/LT2582683T/lt unknown
- 2011-06-14 HU HUE11796324A patent/HUE038265T2/hu unknown
- 2011-06-14 WO PCT/US2011/040398 patent/WO2011159732A1/en active Application Filing
- 2011-06-14 JP JP2013515459A patent/JP5964821B2/ja not_active Expired - Fee Related
- 2011-06-14 ES ES11796324.9T patent/ES2670700T3/es active Active
- 2011-06-14 RS RS20180571A patent/RS57275B1/sr unknown
- 2011-06-14 TR TR2018/06828T patent/TR201806828T4/tr unknown
- 2011-06-14 US US13/704,192 patent/US9216179B2/en active Active
- 2011-06-14 PT PT117963249T patent/PT2582683T/pt unknown
- 2011-06-14 CA CA2802407A patent/CA2802407C/en not_active Expired - Fee Related
- 2011-06-14 PL PL11796324T patent/PL2582683T3/pl unknown
- 2011-06-14 DK DK11796324.9T patent/DK2582683T3/da active
- 2011-06-14 EP EP11796324.9A patent/EP2582683B1/en not_active Revoked
-
2013
- 2013-01-03 ZA ZA2013/00055A patent/ZA201300055B/en unknown
-
2015
- 2015-11-12 US US14/939,963 patent/US20160143889A1/en not_active Abandoned
-
2018
- 2018-05-18 CY CY20181100520T patent/CY1120473T1/el unknown
- 2018-05-18 HR HRP20180780TT patent/HRP20180780T1/hr unknown
- 2018-09-19 US US16/135,153 patent/US20190015392A1/en not_active Abandoned
-
2019
- 2019-02-19 NO NO2019008C patent/NO2019008I1/no unknown
Also Published As
Publication number | Publication date |
---|---|
HUE038265T2 (hu) | 2018-10-29 |
US20190015392A1 (en) | 2019-01-17 |
WO2011159732A1 (en) | 2011-12-22 |
ES2670700T3 (es) | 2018-05-31 |
JP5964821B2 (ja) | 2016-08-03 |
US9216179B2 (en) | 2015-12-22 |
LT2582683T (lt) | 2018-06-11 |
CA2802407C (en) | 2018-01-23 |
RS57275B1 (sr) | 2018-08-31 |
ZA201300055B (en) | 2018-05-30 |
JP2013528650A (ja) | 2013-07-11 |
CY1120473T1 (el) | 2019-07-10 |
US20130178484A1 (en) | 2013-07-11 |
HRP20180780T1 (hr) | 2018-07-13 |
PT2582683T (pt) | 2018-05-25 |
EP2582683B1 (en) | 2018-03-21 |
EP2582683A1 (en) | 2013-04-24 |
US20160143889A1 (en) | 2016-05-26 |
NO2019008I1 (no) | 2019-02-19 |
CA2802407A1 (en) | 2011-12-22 |
EP2582683A4 (en) | 2014-04-30 |
TR201806828T4 (tr) | 2018-06-21 |
SI2582683T1 (en) | 2018-07-31 |
PL2582683T3 (pl) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190015392A1 (en) | Treatment of Gout and Hyperuricemia | |
US9402827B2 (en) | Treatment of gout | |
US20230414539A1 (en) | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent and statin | |
MX2015001732A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de p13k-alfa. | |
CA2914310A1 (en) | Pharmaceutical combinations | |
JP2024001009A (ja) | Pi3k阻害剤であるgdc-0077による癌の治療方法 | |
US20070275989A1 (en) | Therapeutic Treatment | |
WO2015022657A1 (en) | Pharmaceutical combinations | |
US20230404971A1 (en) | Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid | |
US20240197739A1 (en) | Combination Comprising Ribociclib and Amcenestrant | |
AU2008201290B2 (en) | Therapeutic treatment | |
EP3265075B1 (en) | Roneparstat combined therapy of multiple myeloma | |
AU2009272373A1 (en) | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment | |
TW201315471A (zh) | 使用PI3Kβ抑制劑及包括MEK及RAF抑制劑之MAPK通道抑制劑之供治療癌症之組合物及方法 |